CoChat

Infiltration of circulating myeloid cells through CD95L contributes to neurodegeneration in mice

Open access

The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.

Abstract

Neuroinflammation is increasingly recognized as a hallmark of neurodegeneration. Activated central nervous system–resident microglia and infiltrating immune cells contribute to the degeneration of dopaminergic neurons (DNs). However, how the inflammatory process leads to neuron loss and whether blocking this response would be beneficial to disease progression remains largely unknown. CD95 is a mediator of inflammation that has also been proposed as an apoptosis inducer in DNs, but previous studies using ubiquitous deletion of CD95 or CD95L in mouse models of neurodegeneration have generated conflicting results. Here we examine the role of CD95 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridin (MPTP)–induced neurodegeneration using tissue-specific deletion of CD95 or CD95L. We show that DN death is not mediated by CD95-induced apoptosis because deletion of CD95 in DNs does not influence MPTP-induced neurodegeneration. In contrast, deletion of CD95L in peripheral myeloid cells significantly protects against MPTP neurotoxicity and preserves striatal dopamine levels. Systemic pharmacological inhibition of CD95L dampens the peripheral innate response, reduces the accumulation of infiltrating myeloid cells, and efficiently prevents MPTP-induced DN death. Altogether, this study emphasizes the role of the peripheral innate immune response in neurodegeneration and identifies CD95 as potential pharmacological target for neurodegenerative disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20132423

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Selective deletion of CD95 in DNs (CD95f/f;DATcre mice) does not influence dopaminergic neurodegeneration after treatment with MPTP. (A) Scheme of CD95f/f;DATcre mice. (B) Representative images of TH+ neurons in SNpc of control and CD95f/f;DATcre mice. Bar, 100 µm. (C) Quantification of total TH+ DNs in the SNpc at day 6 after last administration of saline or MPTP to WT, CD95f/f, or CD95f/f;DATcre mice. Data are presented as dot plot with median; n = 4–12. ANOVA followed by Newman–Keuls post-hoc test: CD95f/f versus CD95f/f + MPTP: **, P < 0.01; CD95f/f;DATcre versus CD95f/f;DATcre + MPTP: †, P < 0.01; n.s., not significant. (D and E) Quantification of DA metabolite levels and metabolite ratio in striatum at day 6 after last administration of MPTP in saline-treated WT, MPTP-treated CD95f/f, and CD95f/f;DATcre mice. Data are presented as mean ± SEM; n = 6–7. ANOVA followed by Newman–Keuls post-hoc test: ***, P < 0.001.
Figure 1. Selective deletion of CD95 in DNs (CD95f/f;DATcre mice) does not influence dopaminergic neurodegeneration after treatment with MPTP. (A) Scheme of CD95f/f;DATcre mice. (B) Representative images of TH+ neurons in SNpc of control and CD95f/f;DATcre mice. Bar, 100 µm. (C) Quantification of total TH+ DNs in the SNpc at day 6 after last administration of saline or MPTP to WT, CD95f/f, or CD95f/f;DATcre mice. Data are presented as dot plot with median; n = 4–12. ANOVA followed by Newman–Keuls post-hoc test: CD95f/f versus CD95f/f + MPTP: **, P < 0.01; CD95f/f;DATcre versus CD95f/f;DATcre + MPTP: †, P < 0.01; n.s., not significant. (D and E) Quantification of DA metabolite levels and metabolite ratio in striatum at day 6 after last administration of MPTP in saline-treated WT, MPTP-treated CD95f/f, and CD95f/f;DATcre mice. Data are presented as mean ± SEM; n = 6–7. ANOVA followed by Newman–Keuls post-hoc test: ***, P < 0.001.CC BY-NC-SA · PubMed Central
Figure 2. Mice with deletion of CD95L in myeloid cells (CD95Lf/f;LysMcre mice) are more resistant to MPTP. (A) Scheme of CD95Lf/f;LysMcre mice. (B) Quantification of total TH+ DNs in the SNpc at day 6 after last administration of saline or MPTP to CD95Lf/+;LysMcre, CD95f/f, or CD95Lf/f;LysMcre mice. Data are presented as dot plot with median; n = 6. ANOVA followed by Newman–Keuls post-hoc test: control versus CD95Lf/f: *, P < 0.01; CD95Lf/f versus CD95Lf/f;LysMcre: †, P < 0.05. (C) Representative images of TH+ neurons in SNpc of control and CD95Lf/f;LysMcre mice. (D) Representative photomicrographs of SNpc sections immunostained with anti-CD11b from control and CD95Lf/f;LysMcre mice. Note the different morphology of CD11b+ cells in CD95Lf/f and CD95Lf/f;LysMcre mice, as shown in the magnified pictures of anti-CD11b staining in the insets in SNpc. Bars: (C and D) 100 µm (D, insets) 50 µm. (E) Quantification of CD11b+ cells in SNpc. Data are presented as mean ± SEM; n = 6. ANOVA followed by Newman–Keuls post-hoc test: **, P < 0.01; n.s., not significant.
Figure 2. Mice with deletion of CD95L in myeloid cells (CD95Lf/f;LysMcre mice) are more resistant to MPTP. (A) Scheme of CD95Lf/f;LysMcre mice. (B) Quantification of total TH+ DNs in the SNpc at day 6 after last administration of saline or MPTP to CD95Lf/+;LysMcre, CD95f/f, or CD95Lf/f;LysMcre mice. Data are presented as dot plot with median; n = 6. ANOVA followed by Newman–Keuls post-hoc test: control versus CD95Lf/f: *, P < 0.01; CD95Lf/f versus CD95Lf/f;LysMcre: †, P < 0.05. (C) Representative images of TH+ neurons in SNpc of control and CD95Lf/f;LysMcre mice. (D) Representative photomicrographs of SNpc sections immunostained with anti-CD11b from control and CD95Lf/f;LysMcre mice. Note the different morphology of CD11b+ cells in CD95Lf/f and CD95Lf/f;LysMcre mice, as shown in the magnified pictures of anti-CD11b staining in the insets in SNpc. Bars: (C and D) 100 µm (D, insets) 50 µm. (E) Quantification of CD11b+ cells in SNpc. Data are presented as mean ± SEM; n = 6. ANOVA followed by Newman–Keuls post-hoc test: **, P < 0.01; n.s., not significant.CC BY-NC-SA · PubMed Central
Figure 3. Pharmacological neutralization of CD95L protects mice against MPTP toxicity and alters peripheral immune response. (A) Scheme of MPTP and APG112 treatment. (B) Quantification of total TH+ DNs in the SNpc at day 6 after last administration of saline or MPTP of control or APG112-treated mice. ANOVA followed by Newman–Keuls post-hoc test: control versus MPTP: *, P < 0.001; MPTP versus MPTP + APG112: †, P < 0.01. (C) Representative images of TH+ neurons in SNpc of control and APG112-treated mice. Bar, 100 µm. (D) Quantification of striatal DA levels using HPLC at day 6 after last administration of saline or MPTP to control or APG112-treated mice. (E) Calculation of the metabolite ratio [(DOPAC + HVA/DA) × 100] after quantification of striatal DA metabolite levels by HPLC. (D and E) Data are presented as mean ± SEM; n = 8. ANOVA on ranks, Student–Newman–Keuls multiple comparison: *, P < 0.05; **, P < 0.01; ***, P < 0.001. (F) HPLC measurement of striatal MPP+ levels in WT and WT + APG112 mice at 90 min after MPTP injection. Data are presented as mean ± SEM; n = 3. Student’s t test: n.s., not significant. (G) Representative dot plots of blood monocytes and gating scheme of flow cytometry. (H) Quantification of blood monocyte subsets by FACS at day 6 after last administration of saline or MPTP of control or APG112-treated mice. ANOVA followed by Newman–Keuls post-hoc test: *, P < 0.05. (B and H) Data are presented as dot plot with median and were pooled from two independent experiments; n = 16–17.
Figure 3. Pharmacological neutralization of CD95L protects mice against MPTP toxicity and alters peripheral immune response. (A) Scheme of MPTP and APG112 treatment. (B) Quantification of total TH+ DNs in the SNpc at day 6 after last administration of saline or MPTP of control or APG112-treated mice. ANOVA followed by Newman–Keuls post-hoc test: control versus MPTP: *, P < 0.001; MPTP versus MPTP + APG112: †, P < 0.01. (C) Representative images of TH+ neurons in SNpc of control and APG112-treated mice. Bar, 100 µm. (D) Quantification of striatal DA levels using HPLC at day 6 after last administration of saline or MPTP to control or APG112-treated mice. (E) Calculation of the metabolite ratio [(DOPAC + HVA/DA) × 100] after quantification of striatal DA metabolite levels by HPLC. (D and E) Data are presented as mean ± SEM; n = 8. ANOVA on ranks, Student–Newman–Keuls multiple comparison: *, P < 0.05; **, P < 0.01; ***, P < 0.001. (F) HPLC measurement of striatal MPP+ levels in WT and WT + APG112 mice at 90 min after MPTP injection. Data are presented as mean ± SEM; n = 3. Student’s t test: n.s., not significant. (G) Representative dot plots of blood monocytes and gating scheme of flow cytometry. (H) Quantification of blood monocyte subsets by FACS at day 6 after last administration of saline or MPTP of control or APG112-treated mice. ANOVA followed by Newman–Keuls post-hoc test: *, P < 0.05. (B and H) Data are presented as dot plot with median and were pooled from two independent experiments; n = 16–17.CC BY-NC-SA · PubMed Central
Figure 4. Mice with deletion of CD95L in peripheral myeloid cells (CD95Lf/f;LysMcre chimera mice) are resistant to MPTP neurotoxicity. (A) Scheme of CD95Lf/f;LysMcre BM chimera mice. The heads of BM recipient mice were covered with a lead cap during irradiation to avoid irradiation-induced monocyte infiltration. (B) Representative FACS dot plots of CD45.1- and CD45.2-stained blood samples from CD95Lf/f;LysMcre± BM chimera mice. (C) BM reconstitution level of chimera mice before the injection of saline or MPTP. Data are presented as mean ± SEM; n = 6–7. (D) Quantification of total TH+ DNs in the SNpc at day 6 after last administration of saline or MPTP to CD95Lf/f;LysMcre± BM chimera mice. Data are presented as dot plot with median; n = 6–7. (C and D) ANOVA followed by Newman–Keuls post-hoc test: *, P < 0.05; ***, P < 0.001.
Figure 4. Mice with deletion of CD95L in peripheral myeloid cells (CD95Lf/f;LysMcre chimera mice) are resistant to MPTP neurotoxicity. (A) Scheme of CD95Lf/f;LysMcre BM chimera mice. The heads of BM recipient mice were covered with a lead cap during irradiation to avoid irradiation-induced monocyte infiltration. (B) Representative FACS dot plots of CD45.1- and CD45.2-stained blood samples from CD95Lf/f;LysMcre± BM chimera mice. (C) BM reconstitution level of chimera mice before the injection of saline or MPTP. Data are presented as mean ± SEM; n = 6–7. (D) Quantification of total TH+ DNs in the SNpc at day 6 after last administration of saline or MPTP to CD95Lf/f;LysMcre± BM chimera mice. Data are presented as dot plot with median; n = 6–7. (C and D) ANOVA followed by Newman–Keuls post-hoc test: *, P < 0.05; ***, P < 0.001.CC BY-NC-SA · PubMed Central
Figure 5. Myeloid cell infiltration in SNpc demonstrated by staining of microglia marker P2Y12 or monocyte marker CD169. (A) Representative photomicrographs of SNpc sections immunostained with anti-P2Y12, anti-TH, and anti-CD11b from saline-, MPTP-, and MPTP + APG112–treated mice. (B) Representative CD11b single-positive (CD11b+/P2Y12−; as indicated with arrows in b1–b3) and CD11b P2Y12 double-positive (CD11b+/P2Y12+; as indicated with arrows in b4–b6) cells, which are highlighted with dashed rectangles in A. (C) Mosaic acquisition of CD11b single-positive (CD11b+/P2Y12−) area in saline-, MPTP-, and MPTP/APG112-treated mice. Data are presented as mean ± SEM; n = 10. Student’s t test: *, P < 0.05; n.d., not detectable. (D and E) Representative photomicrographs of SNpc sections immunostained with anti-CD169, anti-Iba1, and anti-TH from saline- and MPTP-treated mice. Infiltrating monocytes are CD169+/Iba1+ cells and microglia are CD169−/Iba1+ cells, as arrows indicate in F–H (dashed rectangle in E). Bars: (A, D, and E) 100 µm; (B) 30 µm; (F–H) 20 µm.
Figure 5. Myeloid cell infiltration in SNpc demonstrated by staining of microglia marker P2Y12 or monocyte marker CD169. (A) Representative photomicrographs of SNpc sections immunostained with anti-P2Y12, anti-TH, and anti-CD11b from saline-, MPTP-, and MPTP + APG112–treated mice. (B) Representative CD11b single-positive (CD11b+/P2Y12−; as indicated with arrows in b1–b3) and CD11b P2Y12 double-positive (CD11b+/P2Y12+; as indicated with arrows in b4–b6) cells, which are highlighted with dashed rectangles in A. (C) Mosaic acquisition of CD11b single-positive (CD11b+/P2Y12−) area in saline-, MPTP-, and MPTP/APG112-treated mice. Data are presented as mean ± SEM; n = 10. Student’s t test: *, P < 0.05; n.d., not detectable. (D and E) Representative photomicrographs of SNpc sections immunostained with anti-CD169, anti-Iba1, and anti-TH from saline- and MPTP-treated mice. Infiltrating monocytes are CD169+/Iba1+ cells and microglia are CD169−/Iba1+ cells, as arrows indicate in F–H (dashed rectangle in E). Bars: (A, D, and E) 100 µm; (B) 30 µm; (F–H) 20 µm.CC BY-NC-SA · PubMed Central
Figure 6. Pharmacological neutralization of CD95L reduces infiltration of circulating myeloid cells in SNpc. (A) Scheme of tdTomatoR26f/f;Cx3cr1creER mice. 4 wk after tamoxifen induction, microglia were tdTomato positive and the circulating monocytes were tdTomato negative. (B) Representative CD11b single-positive (CD11b+/tdTomato−; as indicated with arrows in b3 and b4) infiltrating monocytes, which are highlighted with the dashed rectangle in b1. Bars: (b1 and b2) 50 µm; (b3 and b4) 20 µm. (C) Quantification of infiltrating monocytes (CD11b+/tdTomato−) in SNpc of MPTP- and MPTP/APG112-treated mice. Data are presented as dot plot with median; n = 7. Student’s t test: *, P < 0.05.
Figure 6. Pharmacological neutralization of CD95L reduces infiltration of circulating myeloid cells in SNpc. (A) Scheme of tdTomatoR26f/f;Cx3cr1creER mice. 4 wk after tamoxifen induction, microglia were tdTomato positive and the circulating monocytes were tdTomato negative. (B) Representative CD11b single-positive (CD11b+/tdTomato−; as indicated with arrows in b3 and b4) infiltrating monocytes, which are highlighted with the dashed rectangle in b1. Bars: (b1 and b2) 50 µm; (b3 and b4) 20 µm. (C) Quantification of infiltrating monocytes (CD11b+/tdTomato−) in SNpc of MPTP- and MPTP/APG112-treated mice. Data are presented as dot plot with median; n = 7. Student’s t test: *, P < 0.05.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 46

Metadata

Authors
Gao, L., Brenner, D., Llorens-Bobadilla, E., Saiz-Castro, G., Frank, T., Wieghofer, P., Hill, O., Thiemann, M., Karray, S., Prinz, M., Weishaupt, J. H., & Martin-Villalba, A.
Affiliations
  • German Cancer Research Center (DE)
  • Division of Molecular Neurobiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany 1
  • Universitätsmedizin Göttingen (DE)
  • University of Freiburg (DE)
  • Apogenix (Germany) (DE)
  • Inserm (FR)
  • Universität Ulm (DE)
Venue
Journal of Experimental Medicine
Published
2015-03-16
Volume
212
Issue
4
Pages
469-480
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2135833206
Cited by
42
References
56
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 2 · 2018: 9 · 2017: 3 · 2016: 8 · 2015: 4
FWCI
4.28
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • OPUS (Augsburg University) (submittedVersion, cc-by-nc-sa)
  • HAL (submittedVersion)
  • FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
  • GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by-nc-sa)
  • GRO (submittedVersion, cc-by-nc-sa)
Funders
  • Deutsches Krebsforschungszentrum
  • Bundesministerium für Bildung und Forschung
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords
Fas, Fas ligand, neurodegeneration, dopaminergic neurons, MPTP-induced neurotoxicity, neuroinflammation, apoptosis, striatal dopamine, tissue-specific gene deletion
MeSH terms
Animals, Corpus Striatum, Dopamine, Immunity, Innate, Inflammation, Apoptosis, Mice, Knockout, fas Receptor, Parkinsonian Disorders, Myeloid Cells, Mice, Fas Ligand Protein, Dopaminergic Neurons

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.